


Curriculum Vitae

Name	Bhumsuk Keam	
Current Position & Affiliation	Clinical professor Department of Internal Medicine, Seoul National University Hospital	
Country	Korea	

Educational Background

Mar. 1998- Feb. 2002	Seoul National University College of Medicine, Seoul, Korea
Sep. 2004- Feb.2007	Degree of Master in Medicine, Seoul National University College of Medicine, Seoul, Korea
Mar.2007- Aug.2014	Ph.D. in Medicine Seoul National University College of Medicine, Seoul, Korea

Professional Experience

Mar. 2002- Feb. 2003	Internship, Seoul National University Hospital, Seoul, Korea
Mar. 2003- Feb. 2007	Residency Course at Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
May 2010-Feb. 2011	Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Mar. 2011- Feb. 2015	Clinical Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
Mar. 2015- Feb 2020	Clinical Associate Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

Mar. 2020- Present Clinical Professor,
Division of Hematology and Medical Oncology,
Department of Internal Medicine,
Seoul National University Hospital, Seoul, Korea

Professional Organizations

Mar. 2004- Present Korean Cancer Study Group, Full Member
May 2005- Present Korean Society for Hospice and Palliative Care,
Full Member
Apr. 2006- Present Korean Association for Clinical Oncology, Full Member
Sep. 2006- Present American Society of Clinical Oncology, Active Member
Feb. 2008- Present Korean Association of Internal Medicine, Full Member
Sep. 2008- Present European Society for Medical Oncology, Full Member
(ESMO faculty member for the Head and Neck Cancer
faculty group for the period 2019-2023)
Apr. 2012- Present International Association for the Study of Lung Cancer,
Member
Nov. 2012- Present American Association of Cancer Research, Member
Feb. 2016- Present Korean Society for Medical Ethics, Member

Main Scientific Publications

- 1) Sharma P, Sohn J, Shin SJ, Oh DY, **Keam B**, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clin Cancer Res. 2020 Jan 1;26(1):61-70.
- 2) **Keam B**, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncologist. 2019 Jun;24(6):751-e231.

- 3) Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, **Keam B**, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. *Cancer Discov.* 2018 Jul;8(7):812-821.
 - 4) Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, **Keam B**. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. *J Clin Oncol.* 2018 Jan 1;36(1):7-13.
 - 5) Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, **Keam B**, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. *J Clin Oncol.* 2016 Sep 19.
 - 6) Ock CY, **Keam B**, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration. *Clin Cancer Res.* 2016 May 1;22(9):2261-70
-